Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 200

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 200
---
 clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in Kineta’s studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. The enrollment of patients further depends on many factors, including:

| • |     | the size of the patient population and process for identifying patients; |

| • |     | the eligibility criteria for the clinical trial in question; |

| • |     | the availability of an appropriate screening test, as necessary; |

| • |     | the perceived risks and benefits of the product candidate under study; |

| • |     | the efforts to facilitate timely enrollment in clinical trials; |

| • |     | the proximity and availability of clinical trial sites for prospective patients; |

| • |     | the design of the clinical trial; |

| • |     | Kineta’s ability to recruit clinical trial investigators with the appropriate competencies and experience; |

| • |     | Kineta’s ability to obtain and maintain patient consents; |

| • |     | reporting of the preliminary results of any of Kineta’s clinical trials; and |

| • |     | the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial 
 completion.                                                                                                   |

In addition, Kineta’s clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as Kineta’s current product candidates and any future product candidates, and this competition will reduce the number and types of patients available to Kineta because some patients who might have opted to enroll in Kineta’s clinical trials may instead opt to enroll in a clinical trial being conducted by one of Kineta’s competitors. Since the number of qualified clinical investigators is limited, Kineta expects to conduct some of its clinical trials at the same clinical trial sites that some of Kineta’s competitors use, which will reduce the number of patients who are available for Kineta’s clinical trials at such clinical trial sites. Furthermore, even if Kineta is able to enroll a sufficient number of patients for its clinical trials, Kineta may have difficulty maintaining enrollment of such patients in its clinical trials. If Kineta experiences delays in the completion of, or termination of, any clinical trial of its current product candidates and any future product candidates, the commercial prospects of Kineta’s current product candidates and any future product candidates will be harmed, and Kineta’s ability to generate product revenue from such